What We're Reading: Page 389
Industry reads hand-picked by our editors
Dec 18, 2014
-
None
The 11 biggest drug launches to watch in 2015
-
-
The US Patent Office just gave a big gift to biopharma companies
-
Historic: FDA approves first-ever system to cut blood transfusion infections
-
Google Ventures ventures more aggressively into healthcare, life sciences
-
Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign
-
FDA forces Pfizer to put another warning on antipsychotic Geodon
-
-
-
Former Onyx CEO tackles hard-to-treat CNS diseases with new biotech
Dec 17, 2014
-
-
How Teva's CEO is preparing for a 2015 of patent expirations
-
-
The other victims of scuttled AbbVie-Shire deal? Big banks
-
-
FDA approves two new plasma-based tests, expands use of a third
-
Senate bill would give 15 years' data exclusivity to drugs for unmet needs
-
-
-
Pfizer, OPKO reach growth hormone drug pact worth up to $570M
Dec 16, 2014
-
-
Abbott closes Veropharm deal amidst US-Russia political tension
-
-
Indian Supreme Court rejects Bayer's bid to block cheap cancer generic
-
-
Jazz pushing potential $1B rare disease drug through rolling NDA
-
Federal judge: Actavis must keep selling older version of Alzheimer's drug
-
-
Novartis psoriasis drug bests J&J's Stelara in head-to-head trial
-
Dec 15, 2014
-
Philly transit authority launches class action against Gilead over Sovaldi price
-
Compromise: Branded biologics, biosimilar firms reach hard-won agreement
-
-
Teva 2015 revenue forecast $1 billion lower than expected
-
-
Gavi pledges $300M to get Ebola vaccines to hard-hit countries
-
-
-
-
Lawmakers propose new antibiotics pathway to combat superbugs
Dec 12, 2014
-
-
FDA approves new HPV super-vaccine, Merck's Gardasil 9
-
'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden
-
-
Teva launches generic of Pfizer's arthritis med Celebrex in the US
-
-
Merck, NewLink Ebola vax trial suspended over joint pain complaints
-
ICYMI: AARP and GPhA on what to do about generic drug price hikes
-
-
Mylan to foot $20M tax penalty for top execs after inversion merger
Dec 11, 2014
-
Indian company first to the finish line with historic Humira biosimilar
-
A $3B case of bad timing? Merck defends Cubist deal after judge invalidates patents
-
-
-
Feds refuse to hear Sandoz case related to biosimilar development efforts
-
-
After failed Allergan offensive, Valeant finally taking break from M&A focus
-
HHS extends legal immunity to Ebola vaccine makers
-
-
Bluebird shares skyrocket on promising gene therapy-blood disorder data
Dec 10, 2014
-
-
Feds drop wire fraud charges against former Lilly scientists
-
CEO of growing biopharma CRO killed in Maryland small jet crash
-
-
-
Pfizer creating gene therapy platform to expand rare disease efforts
-
-
-
Microsoft co-founder Allen donates $100M to unlock mysteries of the human cell
-
France, Germany, other EU countries suspend Indian generics approvals
Previous
